三生制药集团
Location: China
Employees: 5001-10000
Total raised: $712M
Founded date: 1993
Investors 1
| Date | Name | Website |
| - | LAV | lavfund.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.05.2015 | IPO | $712M | - |
Mentions in press and media 11
| Date | Title | Description |
| 01.11.2023 | CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3SBio for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China | CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and commercialization of nofazinlimab (anti-PD-1 antibody) in mainland China. CStone to retain the rights to nofazinlimab outside mainland China. This ... |
| 25.08.2023 | 3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced | HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximately RMB3,783.8 million, up 22.3% on a yearly ba... |
| 22.03.2023 | 3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2% | HONG KONG, March 21, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today announced its 2022 annual results. In 2022, 3SBio's core biopharmaceutical products posted robust growth, hair health business achiev... |
| 22.03.2023 | 3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2% | HONG KONG, March 22, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today announced its 2022 annual results. In 2022, 3SBio's core biopharmaceutical products posted robust growth, hair health business achiev... |
| 26.08.2021 | 3SBio : announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development | August 25, 2021, Hong Kong --- Chinese leading biopharmaceutical company 3SBio（01530.HK) today unveiled its 2021 interim results. 3SBio maintained strong performance in core businesses, with core products occupying a leading market share. M... |
| 30.03.2021 | 3SBIO INC. 3SBio : announces 2020 annual results, tapping integrated platform advantages for steady growth | Chinese leading biopharmaceutical company 3SBio（01530.HK) today unveiled its 2020 full-year results. The Company maintained stable profitability despite the huge challenge amid the COVID-19 pandemic, while ushering in new milestones. It onc... |
| 09.03.2020 | Numab Therapeutics raises CHF 22M series B round | Numab Therapeutics is an oncology-focused biopharmaceutical company developing a pipeline of multi-specific biotherapeutics in immuno-oncology and immunology for the treatment of severe diseases. With the new funds raised in a Series B roun... |
| 09.03.2020 | Numab Therapeutics raises CHF 22M series B round | |
| 05.09.2017 | Term Sheet — Tuesday, September 5 | CATCH UP Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop SQUEEZED OUT: On Friday, we bid farewell to Juicero, our favorite juicer company to make fun of on Twitter. After raising... |
| 27.05.2015 | GIC & Blackrock among cornerstone investors in 3SBio Inc’s $712m HK IPO | Premium Singapore’s sovereign wealth fund GIC and BlackRock were among cornerstone investors who bought shares to the tune $150 million in Chinese biotech firm 3SBio, ahead of the company’s $712 million Hong Kong initial public offering. Co... |
Show more